Todays Report: The Zacks Investment Research Downgrades Prometic Life Scie Com Npv (PFSCF) to Hold

The Zacks Investment Research Downgrades Prometic Life Scie Com Npv (PFSCF) to Hold

Prometic Life Scie Com Npv (NASDAQ:PFSCF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “ProMetic Life Sciences Inc. is a biopharmaceutical company. The company is involved in bioseparations, plasma-derived therapeutics and small-molecule drug development. Its operating segment consists of Therapeutics and Protein Technology. Therapeutics segment products include PBI-4050 for treatment of fibrosis with chronic kidney diseases, certain cancers and side effects associated with chemotherapy; PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases and PBI-1402 for the treatment of anemia indications. Protein Technology segment provides plasma protein purification system, bioseparation products and prion capture/pathogen removal technology platform. ProMetic Life Sciences Inc. is headquartered in Laval, Canada. “

Prometic Life Scie Com Npv (NASDAQ:PFSCF) opened at 2.3392 on Wednesday. The firm’s 50 day moving average price is $2.24 and its 200-day moving average price is $2.33. Prometic Life Scie Com Npv has a 12-month low of $1.29 and a 12-month high of $2.77. The stock’s market cap is $1.41 billion.

Related posts

Leave a Comment